// App-Quantinova.ai

9058 : Phase 3 study of first-line crizotinib vs pemetrexedcisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).

Researchers

Presenter

  • Shun Lu

Principal Investigators

  • Tony Mok

  • You Lu

  • Jianying Zhou

  • Yuankai Shi

  • Virote Sriuranpong

  • James C. M. Ho

  • Choo Khoon Ong

  • Chun-Ming Tsai

  • Chin-Hee Chung

  • Keith D. Wilner

  • Yiyun Tang

  • Elizabeth Masters

  • Paulina Selaru

  • Yi-Long Wu

Medical Centers

  • Shanghai Chest Hospital, Jiao Tong University, Shanghai, China

  • Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China

  • West China Hospital, West China School of Clinical Medicine, Chengdu, China

  • Respiratory Department, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

  • Cancer Institute/Hospital Chinese Academy of Medical Sciences(CAMS) & Peking Union Medical College(PUMC), Beijing, China

  • Chulalongkorn University/ King Chulalongkorn Memorial Hospital, Bangkok, Thailand

  • University of Hong Kong, Hong Kong, China

  • Hospital Pulau Pinang, Pulau Pinang, Malaysia

  • Pfizer Inc, New York, NY

  • Pfizer Oncology, La Jolla, CA

  • Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangzhou, China

Locations

  • China

  • Taiwan

  • Malaysia

  • United States

  • Thailand

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

Drug/Treatment

  • Carboplatin

  • Pemetrexed

  • Crizotinib

  • Cisplatin

Outcome

  • Positive

Study Design

  • Randomized

  • Cross Over

Phase

  • III

Study Id's

  • NCT01639001

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved